MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on November 8, 2006; DOI: 10.1124/mol.106.030494


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.030494v1
71/2/416    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
Barry Panaretou
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liao, C.
Right arrow Articles by Panaretou, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liao, C.
Right arrow Articles by Panaretou, B.


Received for publication September 22, 2006.
Revised November 7, 2006.
Accepted for publication November 8, 2006.

Genomic screening in vivo reveals the role played by Vacuolar H+ ATPase and cytosolic acidification in sensitivity to DNA damaging agents such as cisplatin

Chunyan Liao 1, Bin Hu 1, Matthew J Arno 1, Barry Panaretou 1*

1 King's College London

* Address correspondence to: E-mail: barry.panaretou{at}kcl.ac.uk

Abstract

Screening the Saccharomyces cerevisiae homozygous diploid deletion library against a sublethal concentration of cisplatin revealed seventy-six strains sensitive to the drug. As expected, the largest category of deletes, representing 40% of the sensitive strains, was composed of strains lacking genes involved in DNA replication and damage repair. Deletes lacking function of the highly conserved vacuolar H+ translocating ATPase (V-ATPase) comprised the category representing the second largest number of sensitive strains. The effect on cell death exhibited by V-ATPase mutants was found to be a general response to various DNA damaging agents as opposed to being specific to cisplatin, as evidenced by sensitivity of the mutants to a DNA alkylating agent, hydroxyurea and UV irradiation. Loss of V-ATPase does not affect DNA repair, as double mutants defective for V-ATPase function and DNA repair pathways were more sensitive to cisplatin than the single mutants. V-ATPase mutants are more prone to DNA damage than wild type cells, indicated by enhanced activation of the DNA damage checkpoint. Vacuole function per se is not cisplatin sensitive, as vacuolar morphology and vacuolar acidification were unaffected by cisplatin in wild type cells. V-ATPase also controls cytoplasmic pH, so the enhanced sensitivity to DNA damage may be associated with the drop in pHi associated with V-ATPase mutants. The increased loss in cell viability induced by cisplatin at lower pH in V-ATPase mutants supports this hypothesis. The loss in viability seen in wild type cells under the same conditions was far less dramatic.


Key words: Mutagenesis/Chimeric approaches, DNA damage and repair, Genetics, Mechanisms of cell killing/apoptosis


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
N. Van Driessche, H. Alexander, J. Min, A. Kuspa, S. Alexander, and G. Shaulsky
Global transcriptional responses to cisplatin in Dictyostelium discoideum identify potential drug targets
PNAS, September 25, 2007; 104(39): 15406 - 15411.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
J. Yadav, S. Muend, Y. Zhang, and R. Rao
A Phenomics Approach in Yeast Links Proton and Calcium Pump Function in the Golgi
Mol. Biol. Cell, April 1, 2007; 18(4): 1480 - 1489.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics